ALPS Advisors’s Juno Therapeutics, Inc. JUNO Stock Holding History

ALPS Advisors’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-91,082	Closed	-$2.02M	–	800
2017 Q1	$2.02M	Sell	91,082 -10,659	-10%	-$229K	0.01%	175
2016 Q4	$1.92M	Sell	101,741 -33,110	-25%	-$810K	0.01%	180
2016 Q3	$4.05M	Sell	134,851 -10,900	-7%	-$339K	0.03%	150
2016 Q2	$5.6M	Buy	+145,751	New	+$6.05M	0.05%	121

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ALPS Advisors's JUNO Position: Q2 2017 in Review

ALPS Advisors sold out of Juno Therapeutics, Inc. (JUNO) in Q2 2017, closing a stake of 91,082 shares — an estimated $2.02M sold.

ALPS Advisors first reported a position in JUNO in Q2 2016 and held it in 4 quarters. The position peaked at $5.6M in Q2 2016. 173 funds tracked by Wall St. Rank hold JUNO as of Q2 2017.

ALPS Advisors reported no remaining Juno Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
ALPS Advisors sold 91,082 Juno Therapeutics, Inc. shares in Q2 2017, an estimated $2.02M.
ALPS Advisors first reported a position in Juno Therapeutics, Inc. in Q2 2016 and held it in 4 quarters.
ALPS Advisors's Juno Therapeutics, Inc. position peaked at $5.6M in Q2 2016.
173 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q2 2017.

Based on ALPS Advisors's 13F filing for Q2 2017, filed 3 Aug 2017.